Raanan Gvirtz

Research Area:
Pharmacological development of dermatological agents
PhD Student. Under the supervision of Dr. Guy Cohen and Dr. Arie Lev Gruzman
Abstract:
Development of a novel IL-33 screening platform for dermatological-relevant disorders
Interleukin‐33 (IL-33) is a tissue-derived nuclear cytokine from the IL-1 family, whose members are associated with pro and anti-inflammatory responses through the MyD88 pathway. IL-1 members are also involved with innate immune responses, which occur during acute inflammation and chronic inflammatory conditions.IL-33 is mostly expressed in endothelial cells, epithelial cells and fibroblasts. Once it is released from the cells, it starts to activate immune cells that express its receptor, ST2 (IL- 1RL1), such as mast cells, group 2 innate lymphoid cells (ILC2s) and regulatory T cells (Tregs). This process leads to an immune response. However, in some cases, such as atopic dermatitis, an over release of IL-33 may lead to a damaging over inflammatory response. To prevent this condition, IL-33 activity can be reduced by endogenous regulations, such as secretion of sST2 and deactivation of the binding activity of IL-33 by cysteine moieties oxidation. However, to date, no specific and effective drug exists to reduce the deleterious effects of IL-33. The objective of this study is to develop a new improved screening system to evaluate new APIs that will be developed by computer modeling and will be synthesized accordingly.
Publications:
Nrf2 Activation by SK-119 Attenuates Oxidative Stress, UVB, and LPS-Induced Damage.
Kahremany S, Babaev I, Gvirtz R, Ogen-Stern N, Azoulay-Ginsburg S, Senderowitz H, Cohen G, Gruzman A.Skin Pharmacol Physiol. 2019;32(4):173-181. doi: 10.1159/000499432. Epub 2019 May 10.PMID: 31079103
Kinetic Cytokine Secretion Profile of LPS-Induced Inflammation in the Human Skin Organ Culture.
Gvirtz R, Ogen-Shtern N, Cohen G.Pharmaceutics. 2020 Mar 25;12(4):299. doi: 10.3390/pharmaceutics12040299.PMID: 32218380